MANNKIND CORP (MNKD) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 393.63M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 40.34M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $393.63M | $40.34M | (m) |
| 2026-03-31 | (m) | $360.78M | $30.54M | (m) |
| 2025-12-31 | (m) | $348.97M | $26.80M | (m) |
| 2025-09-30 | (m) | $313.79M | $17.68M | (m) |
| 2025-06-30 | (m) | $301.74M | $16.38M | (m) |
| 2025-03-31 | (m) | $297.60M | $17.38M | (m) |
| 2024-12-31 | (m) | $285.50M | $17.43M | (m) |
| 2024-09-30 | (m) | $267.20M | $18.73M | (m) |
| 2024-06-30 | (m) | $248.37M | $19.53M | (m) |
| 2024-03-31 | (m) | $224.60M | $19.15M | (m) |
| 2023-12-31 | (m) | $198.96M | $20.86M | (m) |
| 2023-09-30 | (m) | $176.55M | $18.83M | (m) |
| 2023-06-30 | (m) | $158.12M | $19.86M | (m) |
| 2023-03-31 | (m) | $128.40M | $19.25M | (m) |
| 2022-12-31 | (m) | $99.77M | $16.00M | (m) |
| 2022-09-30 | (m) | $76.23M | $16.22M | (m) |
| 2022-06-30 | (m) | $65.61M | $15.01M | (m) |
| 2022-03-31 | (m) | $70.00M | $14.80M | (m) |
| 2021-12-31 | (m) | $75.44M | $16.83M | (m) |
| 2021-09-30 | (m) | $81.37M | $16.19M | (m) |
| 2021-06-30 | (m) | $74.51M | $15.97M | (m) |
| 2021-03-31 | (m) | $66.34M | $15.23M | (m) |
| 2020-12-31 | (m) | $65.14M | $15.08M | (m) |
| 2020-09-30 | (m) | $62.69M | $16.06M | (m) |
| 2020-06-30 | (m) | $61.94M | $19.57M | (m) |
| 2020-03-31 | (m) | $61.83M | $20.22M | (m) |
| 2019-12-31 | (m) | $63.04M | $20.08M | (m) |
| 2019-09-30 | (m) | $63.08M | $20.44M | (m) |
| 2019-06-30 | (m) | $52.95M | $18.65M | (m) |
| 2019-03-31 | (m) | $41.84M | $19.41M | (m) |
| 2018-12-31 | (m) | $27.86M | $19.40M | (m) |
| 2018-09-30 | (m) | $16.36M | (m) | (m) |
| 2018-06-30 | (m) | $13.93M | (m) | (m) |
| 2018-03-31 | (m) | $12.20M | (m) | (m) |
| 2017-12-31 | (m) | $11.74M | (m) | (m) |
| 2017-09-30 | (m) | $19.62M | (m) | (m) |
| 2017-06-30 | (m) | $179.93M | (m) | (m) |
| 2017-03-31 | (m) | $177.77M | (m) | (m) |
| 2016-12-31 | (m) | $174.76M | (m) | (m) |
| 2016-09-30 | (m) | $162.35M | (m) | (m) |
| 2016-06-30 | (m) | $0.00 | (m) | (m) |
| 2016-03-31 | (m) | $0.00 | (m) | (m) |
| 2015-12-31 | (m) | $0.00 | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $0.00 | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $35.00K | (m) | (m) |
| 2012-09-30 | (m) | $35.00K | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $50.00K | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $93.00K | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |